We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -20.00 | -0.16% | 12,106.00 | 12,120.00 | 12,122.00 | 12,190.00 | 12,024.00 | 12,080.00 | 999,558 | 16:35:02 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.55 | 187.98B |
Hot Features
Premium
RNS Number:1883T
AstraZeneca PLC
12 December 2003
AstraZeneca Prilosec(R) Patents Upheld by Federal
Appeals Court
AstraZeneca today announced that a three judge panel of the United States Court
of Appeals for the Federal Circuit upheld the October 2001 decision by U.S.
District Court Judge Barbara S. Jones, finding that Andrx, Genpharm and Cheminor
infringed AstraZeneca's patents for Prilosec(R) (omeprazole), and that the two
formulation patents are not invalid. The Court also upheld the judgment that
Kudco's formulation did not infringe.
AstraZeneca is pleased with the Court's decision upholding the validity of our
patents, again reaffirming the strength of our intellectual property.
Prilosec is a treatment for acid-related stomach disorders.
12 December 2003
Media Enquiries:
Steve Brown, +44 (0) 207 304 5033
Edel McCaffrey, +44 (0) 207 304 5034
Investor Enquiries:
Mina Blair-Robinson, +44 (0) 207 304 5084
Jonathan Hunt, +44 (0) 207 304 5087
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZGMMZLZKGFZG
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
